SCHEDULE: CVI Investments, Heights Capital Boost Aptevo Stake to 8.2%

CVI Investments and Heights Capital Management have disclosed an 8.2% beneficial ownership stake in Aptevo Therapeutics Inc., primarily through warrants.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (collectively, "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Aptevo Therapeutics Inc.
• The Reporting Persons collectively beneficially own 83,854 shares of Aptevo Therapeutics Inc. common stock.
• This represents 8.2% of the company's class of securities.
• The beneficially owned shares consist of shares issuable upon the exercise of warrants.
• The warrants are subject to a limitation, not exercisable to the extent that total beneficial ownership would exceed 9.99%.
• Aptevo Therapeutics Inc. had 936,139 shares outstanding as of November 6, 2025, following a 1-for-18 reverse stock split effective December 30, 2025.
• Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and may exercise voting and dispositive power over the reported shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional stake, even through warrants, suggests investor interest and potential future capital injection, though the immediate impact is limited.

Positives

• A significant stake (8.2%) held by institutional investors like CVI Investments and Heights Capital Management may signal confidence in Aptevo Therapeutics Inc.'s long-term prospects.
• The investment is primarily through warrants, indicating a potential future capital infusion upon exercise, which could strengthen the company's balance sheet.

Negatives

• The beneficial ownership is primarily through warrants, meaning the capital is not yet fully realized by the company until the warrants are exercised.
• The 9.99% exercise limitation on warrants suggests a cap on immediate influence or further accumulation without triggering additional disclosure requirements or potential control implications.

Risks

• The value of the warrants and the underlying shares is subject to market fluctuations and the future performance of Aptevo Therapeutics Inc.
• The exercise of warrants could lead to dilution for existing shareholders if the company issues new shares upon exercise.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional investment in biotechnology companies like Aptevo Therapeutics Inc. often reflects a long-term view on pipeline development or market potential. The use of warrants is a common strategy for investors to gain exposure with a future option to increase their stake, while managing immediate capital deployment and ownership thresholds.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may instill confidence. Future warrant exercise could lead to dilution but also provide capital.
• Company: Potential future capital infusion upon warrant exercise.

Key Dates

Recommendation

The filing indicates a significant institutional stake through warrants, which is generally a positive sign of investor interest and potential future capital. However, it's a disclosure of ownership, not a performance update. Without additional information on Aptevo Therapeutics Inc.'s operational performance, pipeline progress, or financial health, a 'hold' recommendation is prudent. The investment through warrants suggests a long-term view, but the immediate impact on the company's fundamentals is not detailed.

Keywords

Aptevo Therapeutics Inc., CVI Investments, Heights Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Biotechnology, Pharmaceuticals, Investment Management